Navigation Links
PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
Date:5/12/2009

he discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities which have been the basis for collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, Celgene, CV Therapeutics and Schering-Plough. For more information, visit the company's Web site at www.ptcbio.com.

About Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.

About the Spinal Muscular Atrophy Foundation

Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for spinal muscular atrophy through targeted funding of clinical research and novel drug development efforts. Since its inception, the Foundation has awarded over $60 million in sponsored research agreements. In addition, the Foundation is committed to raising awareness and generating support for i
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
2. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
3. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
4. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
5. Nektar Therapeutics Reports First Quarter 2009 Financial Results
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Arno Therapeutics to Deregister its Common Stock under the Exchange Act
8. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
9. United Therapeutics Reports First Quarter 2009 Financial Results
10. Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
11. Richard Giltner Joins United Therapeutics Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
(Date:8/28/2014)... , Aug. 28, 2014   SunTrust Robinson Humphrey ... industry veterans to its equity research team in ... ongoing expansion in equity research demonstrates our commitment ... insights to enhance their investment decision making," said ... STRH.  "We continue to make significant investments in ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 ... , , , , , ... , Cell type , ...
... Kits , , ... Eppendorf Perfectprep Plasmid DNA Isolation Kits are designed to generate , ... automated fluorescent , sequencing, transfection, PCR, and other extremely ... In order to compare yields between our kits and the leading competitor, ...
... , Other important parameters for optimizing electroporation., , , , , , ... , Pulse length , ... Adjustment , of the electroporation buffer , ... Influence , of temperature , ...
Cached Biology Technology:Actinomyces viscosus 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 2Eppendorf Perfectprep Plasmid DNA Isolation , Kits 3Optimizing electroporation parameters 2
(Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) ... the American College of Sports Medicine,s Conference on ... in Miami, Florida. These awards are meant ... and scientists from underrepresented groups into the mainstream ... the participation of young scientists at the American ...
(Date:8/28/2014)... Dyslexia, the most commonly diagnosed learning disability in ... that occurs when the regions of the brain ... The use of non-invasive functional neuroimaging tools has ... dyslexia. However, most prior work has focused on ... a gap in our understanding of how multiple ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Dyslexic readers have disrupted network connections in the brain 2
... National data indicate that milk consumption has declined ... nutritional quality has more than doubled. Although this suggests ... in children,s diets, a new study suggests that in ... related to changes in their consumption of sodas and ...
... at the California Institute of Technology (Caltech) pioneered ... the immune system and neurodevelopmental disorders such as ... postmortem brains and of individuals with autism, as ... between alterations in the immune system and autism ...
... is a vital nutrient for pig growth, but pigs ... the University of Illinois has determined how adding various ... how pigs digest the phosphorus in four different feed ... bottom lines as well as for the environment. ...
Cached Biology News:Sugar-sweetened drinks are not replacing milk in kid's diets 2Sugar-sweetened drinks are not replacing milk in kid's diets 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3Helping pigs to digest phosphorus 2Helping pigs to digest phosphorus 3
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
... gun system, 220-240 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: